biotech – Talk Bio

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

2 weeks ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges

2 weeks ago talkbio0Tagged altretamine/cisplatin/cyclophosphamide protocol, amezalpat, Avastin, biotech, Clearance, Clinical Oncology, Liver and Intrahepatic Biliary Tract Carcinoma, partnerships, Peroxisome Proliferator-Activated Receptors, Phase 3 trial, strategic, Tecentriq, United States Food and Drug Administration

Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy

Alcon Secures Control of Aurion Biotech in Strategic Takeover

4 weeks ago talkbio0Tagged Alcon, AURN001, biotech, Bovichtus, Cell Therapy, CEO, corneal endothelial disease, IPO, stake, Surgical Replantation

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans

2 months ago talkbio0Tagged Alcon, biotech, biotech industry, Bovichtus, Chancery, Corporate, court, Deerfield Management, Delaware, governance, IPO, Legal, Public Offering, research, shareholder

Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery